可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 周永兰,陈清枝,张延斌,等. 雌激素对PDGF诱导的血管平滑肌细胞增殖及细胞周期的影响[J]. 心脏杂志, 2006, 18(6):611-613.
[2] 梁明,韩雅玲. 雌激素在预防血管成形术后再狭窄中的应用[J]. 心脏杂志, 2005, 17(4):398-400.
[3] Dubey RK, Imthurn B, Barton M, et al. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen[J]. Cardiovasc Res, 2005, 66(2):295-306.
[4] Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences[J]. Science, 2005, 308(5728):1583-1587.
[5] Lonard DM, O’Malley BW. The expanding cosmos of nuclear receptor coactivators[J]. Cell, 2006, 125(3):411-414.
[6] Harrington WR, Kim SH, Funk CC, et al. Estrogen dendrimer conjugates that preferentially activate extranuclear, non-genomic versus genomic pathways of estrogen action[J]. Mol Endocrinol, 2006, 20(3):491-502.
[7] Revankar CM, Cimino DF, Sklar LA, et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling[J]. Science, 2005, 307(5715):1625-1630.
[8] Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30[J]. Nat Chem Biol, 2006, 2(4):207-212.
[9] Xin HB, Senbonmatsu T, Cheng DS, et al. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy[J]. Nature, 2002, 416(6878):334-338.
[10]Pelzer T, Loza PA, Hu K, et al. Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction[J]. Circulation, 2005, 111(12):1492-1498.
[11]Bradbury BD, Lash TL, Kaye JA, et al. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina[J]. Cancer, 2005, 103(6):1114-1121.
[12]Barrett-Connor E, Mosca L, Collins P, et al. Effects of Raloxifene on cardiovascular events and breast cancer in postmenopausal women[J]. N Engl J Med, 2006, 355(2):125-137.